Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable'.
The dosage schedule is available in the summary of product characteristics for belzutifan.
The list price for a 90‑tablet pack of 40‑mg belzutifan is £11,936.70 (excluding VAT; BNF online, accessed November 2023).
The company has a commercial arrangement. This makes belzutifan available to the NHS with a discount. The size of the discount is commercial in confidence.